Strategic Financial Concepts LLC Sells 1,258 Shares of Johnson & Johnson $JNJ

Strategic Financial Concepts LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 31.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,715 shares of the company’s stock after selling 1,258 shares during the quarter. Strategic Financial Concepts LLC’s holdings in Johnson & Johnson were worth $415,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. GFG Capital LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $189.02 on Monday. The stock has a market cap of $455.40 billion, a price-to-earnings ratio of 18.25, a P/E/G ratio of 2.19 and a beta of 0.40. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The stock’s 50-day moving average is $183.28 and its 200 day moving average is $167.75.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Analyst Ratings Changes

Several analysts have weighed in on the company. Argus set a $210.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday. Loop Capital set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 22nd. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Finally, Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.